Kole, I. H. Et Al. 2024. Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.. European journal of clinical pharmacology , vol.80, no.11 , 1773-1785.

Kole, I. H., Vural, P., Yurdacan, B., Alemdar, A., & Mutlu, C., (2024). Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.. European journal of clinical pharmacology , vol.80, no.11, 1773-1785.

Kole, Ismail Et Al. "Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.," European journal of clinical pharmacology , vol.80, no.11, 1773-1785, 2024

Kole, Ismail H. Et Al. "Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.." European journal of clinical pharmacology , vol.80, no.11, pp.1773-1785, 2024

Kole, I. H. Et Al. (2024) . "Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.." European journal of clinical pharmacology , vol.80, no.11, pp.1773-1785.

@article{article, author={Ismail Hasan Kole Et Al. }, title={Evaluation of SLC6A2 and CYP2D6 polymorphisms' effects on atomoxetine treatment in attention deficit and hyperactivity disorder.}, journal={European journal of clinical pharmacology}, year=2024, pages={1773-1785} }